9I果冻制作厂官网

目录产物 » BDCA-2 mFc Chimera, Human
Manual
SDS
COAs

BDCA-2 mFc Chimera, Human

BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
￥3500
Z05076-100

产物介绍
Species Human
Protein Construction
mFc (IgG2a) BDCA-2 (Phe46-Ile213)
Accession # Q8WTT0-1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized BDCA-2 mFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind Anti?BDCA?2 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 46.39 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl, 200mM L-arginine (pH 8.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

图例
BDCA-2 MFc Chimera, Human

Immobilized BDCA-2 mFc Chimera, Human, mFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-BDCA-2 Antibody, hFc Tag with the EC50 of 5.7 ng/ml determined by ELISA. ?

BDCA-2 MFc Chimera, Human

BDCA-2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?

<
>

技术背景
Target Background BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
Synonyms BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303;
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.